| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001512 | EBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10012006 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10007858 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10008487 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10009685 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10010472 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10010870 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10011363 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10011435 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10013160 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | OPRM1 |
|---|---|
| DrugBank ID | DB00708 |
| Drug Name | Sufentanil |
| Target ID | BE0000770 |
| UniProt ID | P35372 |
| Regulation Type | agonist |
| PubMed IDs | 11299311; 1688220; 2847746; 3014923; 6131653; 11752352 |
| Citations | Hurle MA: Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001 Apr;77(2):486-92.@@Levron JC: [Pharmacokinetics and pharmacodynamics of morphinomimetics in the central nervous system]. Agressologie. 1991;32(6-7):318-20.@@Ilien B, Galzi JL, Mejean A, Goeldner M, Hirth C: A mu-opioid receptor-filter assay. Rapid estimation of binding affinity of ligands and reversibility of long-lasting ligand-receptor complexes. Biochem Pharmacol. 1988 Oct 15;37(20):3843-51.@@Colpaert FC, Leysen JE, Michiels M, van den Hoogen RH: Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 1986 Jul;65(1):41-9.@@Leysen JE, Gommeren W: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Anilides |
| SMILES | CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1 |
| Pathways | Sufentanil Action Pathway |
| PharmGKB | PA451527 |
| ChEMBL | CHEMBL658 |
